EPRX EPRX
Company Profile ↓Company Overview
EPRX (EPRX) is a publicly traded company listed on with a market capitalization of $336.57M. The valuation, growth and price-trend signals below summarize what matters most to investors and traders evaluating the stock.
Why Investors Should Care
Carries low leverage with a debt-to-equity ratio of 0.19.
Growth & Price Performance
Stock Price Performance
| 1 Year: | +20.45% |
| 6 Months: | -28.56% |
| 3 Months: | -10.87% |
| 1 Month: | -2.56% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMABelow
- RSI (14)51.45 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
No notable strengths flagged.
CONS
- Trading 28.6% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Revenue | - | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - |
| Operating Expenses | - | 7.12M | 8.26M | 6.88M | 16.16M | 15.96M |
| Operating Income | - | -7.12M | -8.26M | -6.88M | -16.16M | -15.96M |
| EBITDA | - | -7.08M | -8.69M | -6.31M | -16.64M | -15.87M |
| Interest Expense | 137 | 0 | 0 | 0 | 0 | - |
| Pretax Income | - | -6.76M | -8.74M | -6.37M | -16.71M | -12.64M |
| Tax Provision | - | 2.79K | 5.58K | -623 | 11.34K | 13.90K |
| Net Income | - | -6.76M | -8.74M | -6.36M | -16.71M | -12.65M |
| Diluted EPS | - | -0.21 | -0.26 | -0.19 | - | -0.23 |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Revenue | - | 0 | 0 | 0 | 0 |
| Cost of Revenue | - | - | - | - | - |
| Gross Profit | - | - | - | - | - |
| Operating Expenses | - | 17.62M | 27.85M | 27.00M | 38.43M |
| Operating Income | - | -17.62M | -27.85M | -27.00M | -38.43M |
| EBITDA | - | -17.86M | -27.60M | -24.97M | -38.35M |
| Interest Expense | - | 982.86K | 1.17M | 603.57K | 0 |
| Pretax Income | - | -18.99M | -28.93M | -25.74M | -38.59M |
| Tax Provision | - | 0 | 36.42K | 1.80K | 19.09K |
| Net Income | - | -18.49M | -28.22M | -25.50M | -38.58M |
| Diluted EPS | - | -0.96 | -1.17 | -0.76 | -1.03 |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Total Assets | - | 19.12M | 20.27M | 34.94M | 86.15M |
| Current Assets | - | 18.59M | 19.80M | 34.44M | 85.10M |
| Cash & Equivalents | - | 18.26M | 19.34M | 33.10M | 80.56M |
| Inventory | - | - | - | - | - |
| Receivables | - | 89.72K | 190.61K | 228.87K | 674.23K |
| Total Liabilities | - | 11.91M | 19.37M | 3.10M | 5.70M |
| Current Liabilities | - | 3.06M | 19.37M | 3.10M | 5.63M |
| Long Term Debt | 7.27M | 8.80M | - | - | - |
| Total Debt | - | 8.99M | 10.45M | 71.86K | 154.36K |
| Total Equity | - | 7.79M | 2.22M | 33.40M | 82.04M |
| Shares Outstanding | - | 21.59M | 27.28M | 35.64M | 51.94M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | - | -14.40M | -20.75M | -29.99M | -28.55M |
| Investing Cash Flow | - | 9.83M | -73.38K | -75.16K | -588.95K |
| Financing Cash Flow | - | 10.80M | 21.08M | 45.78M | 76.06M |
| Capital Expenditure | - | -235.55K | -73.38K | -104.23K | -588.95K |
| Free Cash Flow | - | -14.63M | -20.82M | -30.10M | -29.14M |
| Net Change in Cash | - | 6.24M | 256.97K | 15.71M | 46.92M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - |
| Operating Margin % | - | - | - | - | - |
| Net Margin % | - | - | - | - | - |
| ROE % | - | -237.5% | -1,273.4% | -76.3% | -47.0% |
| ROCE % | - | -109.7% | -3,120.7% | -84.8% | -47.7% |
Shareholding Pattern
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for EPRX
Eupraxia Pharmaceuticals Strengthens Executive Leadership Team to Support Next Phase of Growth
VANCOUVER, British Columbia, July 13, 2026 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. (“Eupraxia” or the “Company”) (TSX: EPRX) (NASDAQ: EPRX), a clinical-stage biotechnology company leveraging its proprietary Diffusphere™ technology…
Eupraxia Pharmaceuticals Strengthens Board with Three Industry Leaders in Drug Development and Commercialization
VANCOUVER, British Columbia, July 07, 2026 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging its proprietary Diffusphere™ technology d…
Eupraxia Pharmaceuticals Announces Voting Results from Annual General Meeting of Shareholders
VANCOUVER, British Columbia, June 19, 2026 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. (“Eupraxia” or the “Company”) (TSX: EPRX) (NASDAQ: EPRX), a clinical-stage biotechnology company leveraging its proprietary Diffusphere™ technology…
Eupraxia Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference
VANCOUVER, British Columbia, May 28, 2026 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging its proprietary Diffusphere™ technology de…
Eupraxia Pharmaceuticals Q1 Loss Narrows
Eupraxia Pharmaceuticals' (EPRX.TO) first-quarter loss narrowed, the company said after trade on Tue
Eupraxia Pharmaceuticals Reports First Quarter 2026 Financial Results
Robust response in highest dose cohort after 36 weeks following a single treatment of EP-104GI Completion of a $63.2 million public offering to enable clinical trials of EP-104GI in additional indications Well-capitalized into H2 2028, beyo…
EPRX — Frequently Asked Questions
What is the current share price of EPRX?
As of 2026-08-05 17:25 PDT, EPRX trades at $6.48 on NASDAQ/NYSE. Its 52-week range is $5.05 to $9.07.
What is the market capitalisation of EPRX?
EPRX has a market capitalisation of $336.57M on NASDAQ/NYSE.
What is the P/E ratio of EPRX?
EPRX trades at a trailing price-to-earnings (P/E) ratio of -6.29. Its price-to-book (P/B) ratio is 4.10.
What is the return on equity (ROE) of EPRX?
EPRX has a return on equity (ROE) of -47.02%. Its return on capital employed (ROCE) is -47.73%.
Is EPRX a good stock to buy?
This page provides a data-driven analysis of EPRX, including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.